semaglutide and tirzepatide equivalent doses SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide produced superior HbA1c reductions Switching Semaglutide to Tirzepatide |

HM: Data curation, Formal analysis, Methodology, Writing review & editing

#Cipla #EliLilly #Yurpeak #Tirzepatide #DiabetesCare #ObesityManagement #Endocrinology #InternalMedicine #HealthcareProfessionals #PharmaNews #MedicalInnovation #CaringForLife #PatientCare #PharmaLeadership #HealthcareIndia Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity

When one person starts a GLP-1 prescription, buying patterns change for an entire household

Balanced Meals : Include a combination of protein diets, healthy fats, and complex carbohydrates in every meal

Characterized MC1R selectivity n.d

Treatment of overdose with PAXLOVID should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient